Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK14 | O94921 | 20/20 | 0.77 |
| ▸ | CCNY | Q8ND76 | 20/20 | 0.77 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.77 |
| ▸ | CDK2 | P24941 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23271031 | 1.00 | CDK14 (0.77) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23271036 | 0.96 | CDK14 (0.76) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23271032 | 0.96 | CDK14 (0.76) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL28524864 | 0.93 | CDK14 (0.71) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23270989 | 0.93 | CDK14 (0.71) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23270990 | 0.93 | CDK14 (0.71) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23271114 | 0.91 | CDK14 (0.76) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23271117 | 0.91 | CDK14 (0.76) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23271135 | 0.91 | CDK14 (0.79) | CDK14CCNYCDK16CDK2 | |
| SCHEMBL23271132 | 0.91 | CDK14 (0.79) | CDK14CCNYCDK16CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187701-B2 | Taire family kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| WO-2023009833-A9 | MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-3810132-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-112367991-A | TAIRE family kinase inhibitors and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169631-A9 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | CDK14 1/4885CCNY 47/4885CDK16 2/4885 |
| US-20210292299-A1 | TAIRE FAMILY KINASE INHIBITORS AND USES THEREOF | CDK14, CDK16, CDK19 | CDK14 1/4885CCNY 47/4885CDK16 2/4885 |
| US-12187701-B2 | Taire family kinase inhibitors and uses thereof | CDK14, CDK16, CDK19 | CDK14 1/4885CCNY 47/4885CDK16 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.